Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

39.54 -0.08 (-0.20%)
Streaming Delayed Price Updated: 12:12 PM EDT, Jun 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 635,477
Open 39.88
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 39.62
Today's Range 39.39 - 39.94
52wk Range 33.76 - 44.31
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma
From Genentech
Via Business Wire
MAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock Soars
The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments. 
Via Stocktwits

Performance

YTD
+13.2%
+13.2%
1 Month
-0.4%
-0.4%
3 Month
-8.9%
-8.9%
6 Month
+15.5%
+15.5%
1 Year
+12.3%
+12.3%

More News

Read More
Roche Stock Slides After Failed Blood Cancer Trial With AbbVie, But Parkinson’s Therapy Progress Boosts Retail Mood
Via Stocktwits
Genentech Provides Update on Phase III Verona Study
From Genentech
Via Business Wire
Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy
Via Benzinga
Topics Death
Exposures Death Product Safety
Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson’s Disease
From Genentech
Via Business Wire
Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy
Via Benzinga
Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study
Via Benzinga
Genentech’s Tecentriq Combined with Lurbinectedin Shows Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer
From Genentech
Via Business Wire
How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma
Via Investor's Business Daily
New Data Show Genentech’s Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer
From Genentech
Via Business Wire
Roche's Multiple Sclerosis Drug Shows Low Disease Activity Over Two Years
Via Benzinga
Genentech’s Fenebrutinib Maintains Near-Complete Suppression of Disease Activity and Disability Progression for up to Two Years in People With Relapsing Multiple Sclerosis
From Genentech
Via Business Wire
Roche Gets Positive Opinion For Approval Of Cancer Therapy In EU: Retail Yet To React
Via Stocktwits
Topics Government
Exposures Political
New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients
From Genentech
Via Business Wire
FDA Approves Genentech’s Susvimo for Diabetic Retinopathy
From Genentech
Via Business Wire
The Smartest Vanguard ETF to Buy With $500 Right Now
Via The Motley Fool
Topics ETFs
Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
From Genentech
Via Business Wire
Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price
Via Investor's Business Daily
Exposures Product Safety
Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda
Via Benzinga
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Via Benzinga
FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases
Via Benzinga
Exposures Product Safety
Why Weight-Loss Developer Stocks Tumbled on Tuesday
Via The Motley Fool
Topics Government
Exposures Political
Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17%
Via Benzinga
Ten-Year APHINITY Data Show Genentech’s Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer
From Genentech
Via Business Wire

Frequently Asked Questions

Is Roche Holding AG Basel American Depositary Shares publicly traded?
Yes, Roche Holding AG Basel American Depositary Shares is publicly traded.
What exchange does Roche Holding AG Basel American Depositary Shares trade on?
Roche Holding AG Basel American Depositary Shares trades on the OTC Traded
What is the ticker symbol for Roche Holding AG Basel American Depositary Shares?
The ticker symbol for Roche Holding AG Basel American Depositary Shares is RHHBY on the OTC Traded
What is the current price of Roche Holding AG Basel American Depositary Shares?
The current price of Roche Holding AG Basel American Depositary Shares is 39.54
When was Roche Holding AG Basel American Depositary Shares last traded?
The last trade of Roche Holding AG Basel American Depositary Shares was at 06/20/25 12:12 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.